Spots Global Cancer Trial Database for ap1903
Every month we try and update this database with for ap1903 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer | NCT01823978 | Castrate Resist... | BPX-201 vaccine... | 18 Years - | Bellicum Pharmaceuticals | |
| Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer | NCT01823978 | Castrate Resist... | BPX-201 vaccine... | 18 Years - | Bellicum Pharmaceuticals | |
| Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | NCT02743611 | Acute Myeloid L... Myelodysplastic... Uveal Melanoma | BPX-701 Rimiducid | 18 Years - | Bellicum Pharmaceuticals | |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer | NCT00868595 | Castrate Resist... | BPX-101 AP1903 | 18 Years - | Bellicum Pharmaceuticals | |
| Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | NCT02786485 | Leukemia Myelodysplastic... Lymphomas Multiple Myelom... Other High-risk... | rivogenlecleuce... Rimiducid | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant | NCT03459170 | Hematologic Mal... | BPX-501 T cells rimiducid | 1 Year - 18 Years | Bellicum Pharmaceuticals | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | NCT03016377 | Acute Lymphobla... Immune System D... Immunoprolifera... | iC9-CAR19 cells Rimiducid Cyclophosphamid... Fludarabine | 3 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | NCT03721068 | Neuroblastoma Osteosarcoma | iC9.GD2.CAR.IL-... Cyclophosphamid... Fludarabine | 18 Months - | UNC Lineberger Comprehensive Cancer Center | |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | NCT01744223 | Acute Lymphobla... Acute Myelogeno... Lymphoma Myelodysplastic... | BPX-501 dose 1 Rimiducid BPX-501 dose 2 BPX-501 dose 3 BPX-501 dose 4 SCT | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant | NCT03459170 | Hematologic Mal... | BPX-501 T cells rimiducid | 1 Year - 18 Years | Bellicum Pharmaceuticals | |
| Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | NCT02487459 | Hematologic Mal... | BPX-501 AP1903 | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer | NCT00868595 | Castrate Resist... | BPX-101 AP1903 | 18 Years - | Bellicum Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
